Sumitomo Dainippon Pharma, Poxel Ink $300M Diabetes Pact Post author:Sam Post published:October 29, 2017 Post category:BioPharma The two companies will jointly develop Imeglimin for the treatment of type 2 diabetes in Japan. Source: BioSpace You Might Also Like How Sweet It Is: Dynavax Finally Wins FDA OK for Hep B Vaccine Heplisav November 9, 2017 Death Count Rises for Patients on Dynavax's Hep B Vaccine But Overall Rate Was Low, Says the FDA July 25, 2017 What You Need to Know About Freenome January 7, 2018
Death Count Rises for Patients on Dynavax's Hep B Vaccine But Overall Rate Was Low, Says the FDA July 25, 2017